Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Solid Biosciences Inc. (SLDB : NSDQ)
 
 • Company Description   
Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts.

Number of Employees: 104

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.54 Daily Weekly Monthly
20 Day Moving Average: 790,242 shares
Shares Outstanding: 112.81 (millions)
Market Capitalization: $61.08 (millions)
Beta: 1.54
52 Week High: $4.92
52 Week Low: $0.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -41.79% -36.22%
12 Week -41.78% -36.83%
Year To Date -69.06% -63.21%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
141 PORTLAND STREET FIFTH FLOOR
-
CAMBRIDGE,MA 02139
USA
ph: 617-337-4680
fax: -
None http://www.solidbio.com
 
 • General Corporate Information   
Officers
Ilan Ganot - Chief Executive Officer; President and Director
Ian F. Smith - Chairman of the Board
Stephen DiPalma - Interim Chief Financial Officer
Martin Freed - Director
Robert Huffines - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 83422E105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 112.81
Most Recent Split Date: (:1)
Beta: 1.54
Market Capitalization: $61.08 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.77 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.33
Price/Cash Flow: -
Price / Sales: 5.00
EPS Growth
vs. Year Ago Period: -15.79%
vs. Previous Quarter: -29.41%
Sales Growth
vs. Year Ago Period: -42.28%
vs. Previous Quarter: -38.97%
ROE
03/31/22 - -37.71
12/31/21 - -31.30
09/30/21 - -35.42
ROA
03/31/22 - -33.77
12/31/21 - -27.97
09/30/21 - -30.86
Current Ratio
03/31/22 - 9.13
12/31/21 - 9.43
09/30/21 - 10.59
Quick Ratio
03/31/22 - 9.13
12/31/21 - 9.43
09/30/21 - 10.59
Operating Margin
03/31/22 - -660.25
12/31/21 - -530.02
09/30/21 - -
Net Margin
03/31/22 - -660.25
12/31/21 - -530.02
09/30/21 - -
Pre-Tax Margin
03/31/22 - -660.25
12/31/21 - -530.02
09/30/21 - -716.04
Book Value
03/31/22 - 1.64
12/31/21 - 1.89
09/30/21 - 2.03
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.12
12/31/21 - 0.14
09/30/21 - 0.16
 

Powered by Zacks Investment Research ©